PBS Datasets
Collection
A collection of datasets from the Australian Pharmaceutical Benefits Scheme (PBS). Updated with a new schedule on the 1st of every month. • 33 items • Updated • 1
res_code stringlengths 6 13 | treatment_phase stringclasses 432
values | authority_method stringclasses 3
values | treatment_of_code float64 4.08k 16.5k ⌀ | restriction_number float64 4.08k 16.5k ⌀ | li_html_text stringlengths 82 10.6k ⌀ | schedule_html_text stringlengths 41 12.3k | note_indicator stringclasses 2
values | caution_indicator stringclasses 2
values | complex_authority_rqrd_ind stringclasses 2
values | assessment_type_code stringclasses 2
values | criteria_relationship stringclasses 1
value | variation_rule_applied stringclasses 2
values | first_listing_date stringdate 1991-08-01 00:00:00 2025-05-01 00:00:00 | schedule_code int64 3.67k 3.67k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10041_6898_R | null | STREAMLINED | 6,898 | 10,041 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe behavioural disturbances</p><br/><p>Patient must have autism spectrum disorder; AND</p> <p>The treatment must be under the supervision of a paediatrician or psychiatrist; AND</p> <p>The treatment must be in combination with non-pharmacologic... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe behavioural disturbances</p><br/><p>Patient must have autism spectrum disorder; AND</p> <p>The treatment must be under the supervision of a paediatrician or psychiatrist; AND</p> <p>The treatment must be in combination with non-pharmacologic... | N | N | N | IMMEDIATE | ALL | N | 2020-01-01 | 3,671 |
10045_10033_R | Initial treatment | STREAMLINED | 10,033 | 10,045 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>Patient must be receiving PBS subsidised vemurafenib concomitantly for this condition.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>Patient must be receiving PBS subsidised vemurafenib concomitantly for this condition.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-01-01 | 3,671 |
10046_10021_R | Continuing treatment, trial of dose reduction or cessation of treatment | AUTHORITY_REQUIRED | 10,021 | 10,046 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Behavioural disturbances</p><br/><p>Continuing treatment, trial of dose reduction or cessation of treatment</p><br/><p>The condition must be characterised by psychotic symptoms and aggression; AND</p> <p>Patient must have dementia of the Alzheimer ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Behavioural disturbances</p><br/><p>Continuing treatment, trial of dose reduction or cessation of treatment</p><br/><p>The condition must be characterised by psychotic symptoms and aggression; AND</p> <p>Patient must have dementia of the Alzheimer ... | N | N | N | IMMEDIATE | ALL | N | 2020-01-01 | 3,671 |
10058_10051_R | Initial treatment | STREAMLINED | 10,051 | 10,058 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>Patient must be receiving PBS-subsidised dabrafenib concomitantly for this condition.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>Patient must be receiving PBS-subsidised dabrafenib concomitantly for this condition.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-01-01 | 3,671 |
10059_10020_R | Initial treatment | STREAMLINED | 10,020 | 10,059 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Behavioural disturbances</p><br/><p>Initial treatment</p><br/><p>The condition must be characterised by psychotic symptoms and aggression; AND</p> <p>Patient must have dementia of the Alzheimer type; AND</p> <p>Patient must have failed to respond t... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Behavioural disturbances</p><br/><p>Initial treatment</p><br/><p>The condition must be characterised by psychotic symptoms and aggression; AND</p> <p>Patient must have dementia of the Alzheimer type; AND</p> <p>Patient must have failed to respond t... | N | N | N | IMMEDIATE | ALL | N | 2020-01-01 | 3,671 |
10061_10061_R | null | STREAMLINED | 10,061 | 10,061 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)</p><br/><p>The condition must be unresectable locally advanced disease or metastatic disease; AND</p> <p>The condition must be World Health Organisation (WHO) grade 1 or 2; AND</... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)</p><br/><p>The condition must be unresectable locally advanced disease or metastatic disease; AND</p> <p>The condition must be World Health Organisation (WHO) grade 1 or 2; AND</... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10063_10063_R | Continuing treatment | STREAMLINED | 10,063 | 10,063 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have previously receive... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have previously receive... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10067_10067_R | Continuing treatment | STREAMLINED | 10,067 | 10,067 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have previously receive... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have previously receive... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10068_10068_R | Continuing treatment | STREAMLINED | 10,068 | 10,068 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Continuing treatment</p><br/><p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have achieved a decrease of at least 30% in intact parathyroid hormon... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Continuing treatment</p><br/><p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have achieved a decrease of at least 30% in intact parathyroid hormon... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10072_10077_R | null | STREAMLINED | 10,077 | 10,072 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)</p><br/><p>The condition must be unresectable locally advanced disease or metastatic disease; AND</p> <p>The condition must be World Health Organisation (WHO) grade 1 or 2; AND</... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)</p><br/><p>The condition must be unresectable locally advanced disease or metastatic disease; AND</p> <p>The condition must be World Health Organisation (WHO) grade 1 or 2; AND</... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10073_10073_R | Initial treatment | AUTHORITY_REQUIRED | 10,073 | 10,073 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Initial treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have failed to respond to ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Secondary hyperparathyroidism</p><br/><p>Initial treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have chronic kidney disease; AND</p> <p>Patient must be on dialysis; AND</p> <p>Patient must have failed to respond to ... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10075_10075_R | null | STREAMLINED | 10,075 | 10,075 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The condition must be unresectable locally advanced diseas... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The condition must be unresectable locally advanced diseas... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10080_10076_R | Initial treatment | AUTHORITY_REQUIRED | 10,076 | 10,080 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia</p><br/><p>Initial treatment</p><br/><p>Must be treated by a metabolic physician; AND</p> <p>Patient must have hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) deficiency.</p> <p align="justify">Patient must have... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia</p><br/><p>Initial treatment</p><br/><p>Must be treated by a metabolic physician; AND</p> <p>Patient must have hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) deficiency.</p> <p align="justify">Patient must have... | N | N | N | IMMEDIATE | ALL | N | 2020-02-01 | 3,671 |
10086_10121_R | null | STREAMLINED | 10,121 | 10,086 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic obstructive pulmonary disease (COPD)</p><br/><p>Patient must have significant symptoms despite regular beta-2 agonist bronchodilator therapy; AND</p> <p>Patient must have experienced at least one severe COPD exacerbation, which required hos... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic obstructive pulmonary disease (COPD)</p><br/><p>Patient must have significant symptoms despite regular beta-2 agonist bronchodilator therapy; AND</p> <p>Patient must have experienced at least one severe COPD exacerbation, which required hos... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10087_10157_R | Initial treatment | STREAMLINED | 10,157 | 10,087 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The condition must be positive for a BRAF V600 mutation; AND</p> <p>The condition must not have been treated previously with PBS-subsidised BRAF inhibitor... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The condition must be positive for a BRAF V600 mutation; AND</p> <p>The condition must not have been treated previously with PBS-subsidised BRAF inhibitor... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10089_4295_R | null | RESTRICTED | 4,295 | 10,089 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Phenylketonuria</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Phenylketonuria</p> <p align="justify">This product is low in folic acid, choline and methionine and is not intended as a sole source of nutrition.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10095_10095_R | null | RESTRICTED | 10,095 | 10,095 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe eye inflammation</p><br/><p>Patient must have had a cataract removed in the treated eye; or</p> <p>Patient must be scheduled for cataract surgery in the treated eye; AND</p> <p>Patient must identify as Aboriginal or Torres Strait Islander.</... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe eye inflammation</p><br/><p>Patient must have had a cataract removed in the treated eye; or</p> <p>Patient must be scheduled for cataract surgery in the treated eye; AND</p> <p>Patient must identify as Aboriginal or Torres Strait Islander.</... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10111_10130_R | Continuing treatment | AUTHORITY_REQUIRED | 10,130 | 10,111 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for trametinib and dabrafenib concomitantly for adjuvant treatment f... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for trametinib and dabrafenib concomitantly for adjuvant treatment f... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10119_10119_R | Initial treatment | AUTHORITY_REQUIRED | 10,119 | 10,119 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be adjuvant to complete surgical resection; AND</p> <p>Patient must have a WHO performance status of 1 or less; AND</p> <p>The... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be adjuvant to complete surgical resection; AND</p> <p>Patient must have a WHO performance status of 1 or less; AND</p> <p>The... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10120_10120_R | Continuing treatment | AUTHORITY_REQUIRED | 10,120 | 10,120 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment following complete surgical resec... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, IIIC, IIID or Stage IV malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment following complete surgical resec... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10129_10148_R | Initial treatment | AUTHORITY_REQUIRED | 10,148 | 10,129 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be adjuvant to complete surgical resection; AND</p> <p>The condition must be positive for a BRAF V600 mutation; AND</p> <p>P... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The treatment must be adjuvant to complete surgical resection; AND</p> <p>The condition must be positive for a BRAF V600 mutation; AND</p> <p>P... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10138_10138_R | null | STREAMLINED | 10,138 | 10,138 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic.</p> <p align="justify">P... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10161_10161_R | null | STREAMLINED | 10,161 | 10,161 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic.</p> <p align="justify">P... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10164_10125_R | Initial treatment 2 | STREAMLINED | 10,125 | 10,164 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Initial treatment 2</p><br/><p>Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy; AND</p> <p>The condition must be non-squamous ty... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Initial treatment 2</p><br/><p>Patient must be undergoing combination treatment with bevacizumab and platinum-doublet chemotherapy; AND</p> <p>The condition must be non-squamous ty... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10185_5883_R | null | RESTRICTED | 5,883 | 10,185 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cellulitis</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Cellulitis</p> | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10200_10116_R | Continuing treatment | STREAMLINED | 10,116 | 10,200 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised therapy for HIV infection.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised therapy for HIV infection.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10205_10206_R | Initial treatment | STREAMLINED | 10,206 | 10,205 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Extensive-stage small cell lung cancer</p><br/><p>Initial treatment</p><br/><p>The condition must be previously untreated; AND</p> <p>Patient must have a WHO performance status of 0 or 1; AND</p> <p>The treatment must be in combination with etoposi... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Extensive-stage small cell lung cancer</p><br/><p>Initial treatment</p><br/><p>The condition must be previously untreated; AND</p> <p>Patient must have a WHO performance status of 0 or 1; AND</p> <p>The treatment must be in combination with etoposi... | N | N | N | IMMEDIATE | ALL | N | 2020-03-01 | 3,671 |
10207_10210_R | Initial treatment | STREAMLINED | 10,210 | 10,207 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Initial treatment</p><br/><p>Must be treated by a neurologist; AND</p> <p>The treatment must be in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent; ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Initial treatment</p><br/><p>Must be treated by a neurologist; AND</p> <p>The treatment must be in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent; ... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10209_10208_R | Continuing treatment | STREAMLINED | 10,208 | 10,209 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been treated with PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must not be given concomitantly wi... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been treated with PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must not be given concomitantly wi... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10211_10310_R | Continuing treatment | STREAMLINED | 10,310 | 10,211 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Metastatic (Stage IV) adenocarcinoma of the stomach or gastro-oesophageal junction</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Metastatic (Stage IV) adenocarcinoma of the stomach or gastro-oesophageal junction</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must ... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10249_10248_R | null | AUTHORITY_REQUIRED | 10,248 | 10,249 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic hepatitis C infection</p><br/><p>Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND</p> <p>Patient must be taking this drug as part of a regimen set out in the matrix in the Gener... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic hepatitis C infection</p><br/><p>Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND</p> <p>Patient must be taking this drug as part of a regimen set out in the matrix in the Gener... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10252_10252_R | Initial treatment | STREAMLINED | 10,252 | 10,252 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Metastatic (Stage IV) adenocarcinoma of the stomach or gastro-oesophageal junction</p><br/><p>Initial treatment</p><br/><p>Patient must have a WHO performance status of 1 or less; AND</p> <p>Patient must have previously received at least two prior ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Metastatic (Stage IV) adenocarcinoma of the stomach or gastro-oesophageal junction</p><br/><p>Initial treatment</p><br/><p>Patient must have a WHO performance status of 1 or less; AND</p> <p>Patient must have previously received at least two prior ... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10253_10212_R | 3 weekly treatment regimen | STREAMLINED | 10,212 | 10,253 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Early HER2 positive breast cancer</p><br/><p>3 weekly treatment regimen</p><br/><p>Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant); AND</p> <p>The treatment must not be used in a patient with a left ventricu... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Early HER2 positive breast cancer</p><br/><p>3 weekly treatment regimen</p><br/><p>Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant); AND</p> <p>The treatment must not be used in a patient with a left ventricu... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10257_10257_R | Continuing first-line treatment of metastatic disease, as monotherapy, where concomitant bevacizumab has ceased due to intolerance - 4 weekly treatment regimen | STREAMLINED | 10,257 | 10,257 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing first-line treatment of metastatic disease, as monotherapy, where concomitant bevacizumab has ceased due to intolerance - 4 weekly treatment regimen</p><br/><p>Patient m... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing first-line treatment of metastatic disease, as monotherapy, where concomitant bevacizumab has ceased due to intolerance - 4 weekly treatment regimen</p><br/><p>Patient m... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10258_10215_R | Continuing treatment - 4 weekly treatment regimen | STREAMLINED | 10,215 | 10,258 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic non-small cell lung cancer</p><br/><p>Continuing treatment - 4 weekly treatment regimen</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic non-small cell lung cancer</p><br/><p>Continuing treatment - 4 weekly treatment regimen</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treat... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10267_10268_R | null | AUTHORITY_REQUIRED | 10,268 | 10,267 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic hepatitis C infection</p><br/><p>Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND</p> <p>Patient must be taking this drug as part of a regimen set out in the matrix in the Gener... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic hepatitis C infection</p><br/><p>Patient must meet the criteria set out in the General Statement for Drugs for the Treatment of Hepatitis C; AND</p> <p>Patient must be taking this drug as part of a regimen set out in the matrix in the Gener... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10269_10306_R | Continuing treatment | STREAMLINED | 10,306 | 10,269 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for this drug; AND</p> <p>Patient must be receiving PBS-subsidised encorafenib ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for this drug; AND</p> <p>Patient must be receiving PBS-subsidised encorafenib ... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10270_10271_R | Initial treatment | STREAMLINED | 10,271 | 10,270 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The condition must be positive for a BRAF V600 mutation; AND</p> <p>The condition must not have been treated previously with PBS-subsidised BRAF inhibitor... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>The condition must be positive for a BRAF V600 mutation; AND</p> <p>The condition must not have been treated previously with PBS-subsidised BRAF inhibitor... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10277_10216_R | Continuing first-line treatment of metastatic disease - 3 weekly treatment regimen | STREAMLINED | 10,216 | 10,277 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing first-line treatment of metastatic disease - 3 weekly treatment regimen</p><br/><p>Patient must be undergoing combination treatment with bevacizumab until disease progre... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Stage IV (metastatic) non-small cell lung cancer (NSCLC)</p><br/><p>Continuing first-line treatment of metastatic disease - 3 weekly treatment regimen</p><br/><p>Patient must be undergoing combination treatment with bevacizumab until disease progre... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10288_10250_R | Initial treatment | AUTHORITY_REQUIRED | 10,250 | 10,288 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Autosomal dominant polycystic kidney disease (ADPKD)</p><br/><p>Initial treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have an estimated glomerular filtration rate (eGFR) between 30 and 89 mL/min 1.73 m2 at the init... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Autosomal dominant polycystic kidney disease (ADPKD)</p><br/><p>Initial treatment</p><br/><p>Must be treated by a nephrologist; AND</p> <p>Patient must have an estimated glomerular filtration rate (eGFR) between 30 and 89 mL/min 1.73 m2 at the init... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10289_10328_R | Initial treatment | STREAMLINED | 10,328 | 10,289 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>Patient must be receiving PBS-subsidised encorafenib concomitantly for this condition.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Initial treatment</p><br/><p>Patient must be receiving PBS-subsidised encorafenib concomitantly for this condition.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10290_6013_R | Continuing treatment | STREAMLINED | 6,013 | 10,290 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for this drug; AND</p> <p>Patient must have stable or responding disease.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been issued with an authority prescription for this drug; AND</p> <p>Patient must have stable or responding disease.</p> <... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10291_10251_R | Initial treatment | STREAMLINED | 10,251 | 10,291 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Initial treatment</p><br/><p>Must be treated by a neurologist; AND</p> <p>The treatment must be in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent; ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Initial treatment</p><br/><p>Must be treated by a neurologist; AND</p> <p>The treatment must be in combination with two or more anti-epileptic drugs which includes one second-line adjunctive agent; ... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10292_10213_R | Continuing treatment (weekly regimen) | STREAMLINED | 10,213 | 10,292 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Early HER2 positive breast cancer</p><br/><p>Continuing treatment (weekly regimen)</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must not be used in a patient w... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Early HER2 positive breast cancer</p><br/><p>Continuing treatment (weekly regimen)</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must not be used in a patient w... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10307_10324_R | Initial treatment | STREAMLINED | 10,324 | 10,307 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial treatment</p><br/><p>Must be treated by a medical practitioner or an authorised nurse practitioner in consultation with a medical practitioner; AND</p> <p>Patient must be antiretroviral treatment naive; or</p> <p>Pa... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Initial treatment</p><br/><p>Must be treated by a medical practitioner or an authorised nurse practitioner in consultation with a medical practitioner; AND</p> <p>Patient must be antiretroviral treatment naive; or</p> <p>Pa... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10308_10309_R | Initial treatment | STREAMLINED | 10,309 | 10,308 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Metastatic colorectal cancer</p><br/><p>Initial treatment</p><br/><p>Patient must have a WHO performance status of 1 or less; AND</p> <p>Patient must have previously received treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemothera... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Metastatic colorectal cancer</p><br/><p>Initial treatment</p><br/><p>Patient must have a WHO performance status of 1 or less; AND</p> <p>Patient must have previously received treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemothera... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10311_10294_R | Continuing treatment (3 weekly regimen) | STREAMLINED | 10,294 | 10,311 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Early HER2 positive breast cancer</p><br/><p>Continuing treatment (3 weekly regimen)</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must not be used in a patient... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Early HER2 positive breast cancer</p><br/><p>Continuing treatment (3 weekly regimen)</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must not be used in a patient... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10318_10297_R | Continuing treatment - 3 weekly treatment regimen | STREAMLINED | 10,297 | 10,318 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic non-small cell lung cancer</p><br/><p>Continuing treatment - 3 weekly treatment regimen</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Locally advanced or metastatic non-small cell lung cancer</p><br/><p>Continuing treatment - 3 weekly treatment regimen</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treat... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10323_6890_R | null | RESTRICTED | 6,890 | 10,323 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Dietary management of conditions requiring a source of medium chain triglycerides</p><br/><p>Patient must have fat malabsorption due to liver disease; or</p> <p>Patient must have fat malabsorption due to short gut syndrome; or</p> <p>Patient must h... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Dietary management of conditions requiring a source of medium chain triglycerides</p><br/><p>Patient must have fat malabsorption due to liver disease; or</p> <p>Patient must have fat malabsorption due to short gut syndrome; or</p> <p>Patient must h... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10325_10330_R | Continuing treatment | STREAMLINED | 10,330 | 10,325 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been treated with PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must be unable to take a solid dose form... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Intractable partial epileptic seizures</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously been treated with PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must be unable to take a solid dose form... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10329_10317_R | Continuing treatment | STREAMLINED | 10,317 | 10,329 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a medical practitioner or an authorised nurse practitioner in consultation with a medical practitioner; AND</p> <p>Patient must have previously received PBS-subsidised ther... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>HIV infection</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a medical practitioner or an authorised nurse practitioner in consultation with a medical practitioner; AND</p> <p>Patient must have previously received PBS-subsidised ther... | N | N | N | IMMEDIATE | ALL | N | 2020-04-01 | 3,671 |
10352_10362_R | null | STREAMLINED | 10,362 | 10,352 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic hepatitis B infection</p><br/><p>Patient must be in the third trimester of pregnancy; AND</p> <p>Patient must have elevated HBV DNA levels greater than 200,000 IU/mL (1,000,000 copies/mL), in conjunction with documented hepatitis B infectio... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic hepatitis B infection</p><br/><p>Patient must be in the third trimester of pregnancy; AND</p> <p>Patient must have elevated HBV DNA levels greater than 200,000 IU/mL (1,000,000 copies/mL), in conjunction with documented hepatitis B infectio... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10353_10363_R | null | STREAMLINED | 10,363 | 10,353 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic; AND</p> <p>Patient must ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic; AND</p> <p>Patient must ... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10365_10355_R | Continuing treatment | AUTHORITY_REQUIRED | 10,355 | 10,365 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) deficiency</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a metabolic physician; or</p> <p>Must be treated by a nurse practitioner experienced in the treatment of phenylke... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) deficiency</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a metabolic physician; or</p> <p>Must be treated by a nurse practitioner experienced in the treatment of phenylke... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10370_N | null | null | null | null | null | <p/><p align="justify">In first-line usage, effectiveness and tolerance may be improved when irinotecan is combined with an infusional 5-fluorouracil regimen. </p><p/> | Y | N | N | null | null | N | 2014-04-01 | 3,671 |
10378_10388_R | Continuing treatment | STREAMLINED | 10,388 | 10,378 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Familial homozygous hypercholesterolaemia</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must be in conjunction with dietary ther... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Familial homozygous hypercholesterolaemia</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>The treatment must be in conjunction with dietary ther... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10381_10390_R | Continuing treatment | AUTHORITY_REQUIRED | 10,390 | 10,381 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a metabolic physician; or</p> <p>Must be treated by a nurse practitioner experienced in the treatment of phenylketonuria in consultation with a metabolic physician... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a metabolic physician; or</p> <p>Must be treated by a nurse practitioner experienced in the treatment of phenylketonuria in consultation with a metabolic physician... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10395_10375_R | null | STREAMLINED | 10,375 | 10,395 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic; AND</p> <p>Patient must ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Advanced Parkinson disease</p><br/><p>Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND</p> <p>The treatment must be commenced in a hospital-based movement disorder clinic; AND</p> <p>Patient must ... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10396_10391_R | Initial treatment | AUTHORITY_REQUIRED | 10,391 | 10,396 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) deficiency</p><br/><p>Initial treatment</p><br/><p>Must be treated by a metabolic physician; AND</p> <p>Patient must have hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) de... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) deficiency</p><br/><p>Initial treatment</p><br/><p>Must be treated by a metabolic physician; AND</p> <p>Patient must have hyperphenylalaninaemia (HPA) due to tetrahydrobiopterin (BH4) de... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10401_10410_R | null | STREAMLINED | 10,410 | 10,401 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have a pin-site infection; or</p> <p>Patient must have an infection following cardiac device insertion; or</p> <p>Patient must have acute otitis externa; or</p> <p>Patient must have streptococcal pharyngitis or ton... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have a pin-site infection; or</p> <p>Patient must have an infection following cardiac device insertion; or</p> <p>Patient must have acute otitis externa; or</p> <p>Patient must have streptococcal pharyngitis or ton... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10404_10404_R | null | STREAMLINED | 10,404 | 10,404 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have a condition requiring prolonged oral antibiotic therapy.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have a condition requiring prolonged oral antibiotic therapy.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10406_10402_R | null | STREAMLINED | 10,402 | 10,406 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must be a male with acute cystitis; or</p> <p>Patient must have pyelonephritis; or</p> <p>Patient must have a tooth avulsion; or</p> <p>Patient must have salmonella enteritis; or</p> <p>Patient must have community acqui... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must be a male with acute cystitis; or</p> <p>Patient must have pyelonephritis; or</p> <p>Patient must have a tooth avulsion; or</p> <p>Patient must have salmonella enteritis; or</p> <p>Patient must have community acqui... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10408_10405_R | null | STREAMLINED | 10,405 | 10,408 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must be a male with acute cystitis; or</p> <p>Patient must have a condition requiring prolonged oral antibiotic therapy.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must be a male with acute cystitis; or</p> <p>Patient must have a condition requiring prolonged oral antibiotic therapy.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10409_10412_R | null | STREAMLINED | 10,412 | 10,409 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have impaired renal function; AND</p> <p>Patient must have a pin-site infection; or</p> <p>Patient must have an infection following cardiac device insertion; or</p> <p>Patient must have acute otitis externa; or</p>... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have impaired renal function; AND</p> <p>Patient must have a pin-site infection; or</p> <p>Patient must have an infection following cardiac device insertion; or</p> <p>Patient must have acute otitis externa; or</p>... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10411_10413_R | null | STREAMLINED | 10,413 | 10,411 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have periorbital (preseptal) cellulitis; or</p> <p>Patient must have postpartum endometritis; or</p> <p>Patient must have an exacerbation of bronchiectasis; or</p> <p>Patient must have pyelonephritis; or</p> <p>Pat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Infection</p><br/><p>Patient must have periorbital (preseptal) cellulitis; or</p> <p>Patient must have postpartum endometritis; or</p> <p>Patient must have an exacerbation of bronchiectasis; or</p> <p>Patient must have pyelonephritis; or</p> <p>Pat... | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10416_10416_R | null | STREAMLINED | 10,416 | 10,416 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Community acquired pneumonia</p><br/><p>Patient must have community acquired pneumonia.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Community acquired pneumonia</p><br/><p>Patient must have community acquired pneumonia.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-05-01 | 3,671 |
10430_10431_R | Continuing treatment | AUTHORITY_REQUIRED | 10,431 | 10,430 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Continuing treatment</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have de... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Continuing treatment</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have de... | N | N | N | IMMEDIATE | ALL | N | 2020-06-01 | 3,671 |
10437_10482_R | null | STREAMLINED | 10,482 | 10,437 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Mild asthma</p><br/><p>Patient must have asthma and require an anti-inflammatory reliever therapy; AND</p> <p>Patient must not be on a concomitant single agent long-acting-beta-2-agonist (LABA); AND</p> <p>Patient must be aged 12 years or over.</p>... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Mild asthma</p><br/><p>Patient must have asthma and require an anti-inflammatory reliever therapy; AND</p> <p>Patient must not be on a concomitant single agent long-acting-beta-2-agonist (LABA); AND</p> <p>Patient must be aged 12 years or over.</p>... | N | N | N | IMMEDIATE | ALL | N | 2020-06-01 | 3,671 |
10463_10464_R | null | STREAMLINED | 10,464 | 10,463 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Mild asthma</p><br/><p>Patient must have asthma and require an anti-inflammatory reliever therapy; AND</p> <p>Patient must not be on a concomitant single agent long-acting-beta-2-agonist (LABA).</p> <p align="justify">Device (inhaler) technique sho... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Mild asthma</p><br/><p>Patient must have asthma and require an anti-inflammatory reliever therapy; AND</p> <p>Patient must not be on a concomitant single agent long-acting-beta-2-agonist (LABA).</p> <p align="justify">Device (inhaler) technique sho... | N | N | N | IMMEDIATE | ALL | N | 2020-06-01 | 3,671 |
10496_10521_R | Continuing treatment - 3 weekly treatment regimen | STREAMLINED | 10,521 | 10,496 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Extensive-stage small cell lung cancer</p><br/><p>Continuing treatment - 3 weekly treatment regimen</p><br/><p>The treatment must be as monotherapy; AND</p> <p>Patient must have previously received PBS-subsidised treatment with this drug for this c... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Extensive-stage small cell lung cancer</p><br/><p>Continuing treatment - 3 weekly treatment regimen</p><br/><p>The treatment must be as monotherapy; AND</p> <p>Patient must have previously received PBS-subsidised treatment with this drug for this c... | N | N | N | IMMEDIATE | ALL | N | 2020-07-01 | 3,671 |
10504_10499_R | null | AUTHORITY_REQUIRED | 10,499 | 10,504 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Benign prostatic hyperplasia</p><br/><p>Patient must have lower urinary tract symptoms.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Benign prostatic hyperplasia</p><br/><p>Patient must have lower urinary tract symptoms.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-07-01 | 3,671 |
10505_10498_R | null | STREAMLINED | 10,498 | 10,505 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Nausea and vomiting</p><br/><p>The condition must be associated with radiotherapy being used to treat malignancy; or</p> <p>The condition must be associated with oral chemotherapy being used to treat malignancy.</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Nausea and vomiting</p><br/><p>The condition must be associated with radiotherapy being used to treat malignancy; or</p> <p>The condition must be associated with oral chemotherapy being used to treat malignancy.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-07-01 | 3,671 |
10509_10509_R | Continuing treatment - 4 weekly treatment regimen | STREAMLINED | 10,509 | 10,509 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Extensive-stage small cell lung cancer</p><br/><p>Continuing treatment - 4 weekly treatment regimen</p><br/><p>The treatment must be as monotherapy; AND</p> <p>Patient must have previously received PBS-subsidised treatment with this drug for this c... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Extensive-stage small cell lung cancer</p><br/><p>Continuing treatment - 4 weekly treatment regimen</p><br/><p>The treatment must be as monotherapy; AND</p> <p>Patient must have previously received PBS-subsidised treatment with this drug for this c... | N | N | N | IMMEDIATE | ALL | N | 2020-07-01 | 3,671 |
10518_10459_R | Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | AUTHORITY_REQUIRED | 10,459 | 10,518 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in bio... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in bio... | N | N | Y | IMMEDIATE | ALL | N | 2020-07-01 | 3,671 |
10531_9547_R | null | STREAMLINED | 9,547 | 10,531 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe spasticity of the upper limb following an acute event</p><br/><p>The condition must be moderate to severe spasticity of the upper limb/s following an acute event, defined as a Modified Ashworth Scale rating of 3 or more; AND</p> ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Moderate to severe spasticity of the upper limb following an acute event</p><br/><p>The condition must be moderate to severe spasticity of the upper limb/s following an acute event, defined as a Modified Ashworth Scale rating of 3 or more; AND</p> ... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10574_10538_R | null | STREAMLINED | 10,538 | 10,574 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Asthma</p><br/><p>Patient must have failed PBS-subsidised fluticasone proprionate and salmeterol as a fixed dose combination for this condition; AND</p> <p>Must be treated by a respiratory physician; or</p> <p>Must be treated by a paediatrician.</p... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Asthma</p><br/><p>Patient must have failed PBS-subsidised fluticasone proprionate and salmeterol as a fixed dose combination for this condition; AND</p> <p>Must be treated by a respiratory physician; or</p> <p>Must be treated by a paediatrician.</p... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10586_9519_R | Induction treatment - balance of supply | AUTHORITY_REQUIRED | 9,519 | 10,586 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute lymphoblastic leukaemia</p><br/><p>Induction treatment - balance of supply</p><br/><p>The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less; AND</p... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p align="justify">Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.</p> <p>Acute lymphoblastic leuk... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10589_5937_R | Episodic treatment | STREAMLINED | 5,937 | 10,589 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Recurrent moderate to severe genital herpes</p><br/><p>Episodic treatment</p> <p align="justify">Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desira... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Recurrent moderate to severe genital herpes</p><br/><p>Episodic treatment</p> <p align="justify">Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desira... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10604_10434_R | Continuing treatment - balance of supply | AUTHORITY_REQUIRED | 10,434 | 10,604 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks of treatment; AND... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Non-radiographic axial spondyloarthritis</p><br/><p>Continuing treatment - balance of supply</p><br/><p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks of treatment; AND... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10615_N | null | null | null | null | null | <p align="justify">This drug is not PBS-subsidised for the treatment of chronic obstructive pulmonary disease (COPD).</p> | Y | N | N | null | null | N | 2014-12-01 | 3,671 |
10621_9369_R | Consolidation treatment | AUTHORITY_REQUIRED | 9,369 | 10,621 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute lymphoblastic leukaemia</p><br/><p>Consolidation treatment</p><br/><p>Patient must have previously received PBS-subsidised induction treatment with this drug for this condition; AND</p> <p>Patient must have achieved a complete remission; or</... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p align="justify">Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.</p> <p>Acute lymphoblastic leuk... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10622_9601_R | Consolidation treatment | AUTHORITY_REQUIRED | 9,601 | 10,622 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute lymphoblastic leukaemia</p><br/><p>Consolidation treatment</p><br/><p>Patient must have previously received PBS-subsidised induction treatment with this drug for this condition; AND</p> <p>Patient must have achieved a complete remission; or</... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p align="justify">Careful monitoring of patients is required due to risk of developing hepatotoxicity, including life-threatening hepatic veno-occlusive disease, and the increased risk of post-haematopoietic stem cell transplant non-relapse mortality... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10623_5937_R | Episodic treatment | STREAMLINED | 5,937 | 10,623 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Recurrent moderate to severe genital herpes</p><br/><p>Episodic treatment</p> <p align="justify">Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desira... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Recurrent moderate to severe genital herpes</p><br/><p>Episodic treatment</p> <p align="justify">Microbiological confirmation of diagnosis [viral culture, antigen detection or nucleic acid amplification by polymerase chain reaction (PCR)] is desira... | N | N | N | IMMEDIATE | ALL | N | 2020-08-01 | 3,671 |
10648_5789_R | null | STREAMLINED | 5,789 | 10,648 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe intractable psoriasis</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe intractable psoriasis</p> <p align="justify">Care must be taken to comply with the provisions of State/Territory law when prescribing this drug.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-09-01 | 3,671 |
10656_5727_R | null | STREAMLINED | 5,727 | 10,656 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe disorders of keratinisation</p> | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe disorders of keratinisation</p> <p align="justify">Care must be taken to comply with the provisions of State/Territory law when prescribing this drug.</p> | N | N | N | IMMEDIATE | ALL | N | 2020-09-01 | 3,671 |
10676_10676_R | Continuing treatment - 6 weekly treatment regimen | AUTHORITY_REQUIRED | 10,676 | 10,676 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Continuing treatment - 6 weekly treatment regimen</p><br/><p>Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment fo... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Continuing treatment - 6 weekly treatment regimen</p><br/><p>Patient must have previously been issued with an authority prescription for this drug for adjuvant treatment fo... | N | N | N | IMMEDIATE | ALL | N | 2020-09-01 | 3,671 |
10680_10705_R | Continuing treatment - 3 weekly treatment regimen | STREAMLINED | 10,705 | 10,680 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment - 3 weekly treatment regimen</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must have previously been iss... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment - 3 weekly treatment regimen</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must have previously been iss... | N | N | N | IMMEDIATE | ALL | N | 2020-09-01 | 3,671 |
10700_10688_R | Initial treatment - 6 weekly treatment regimen | AUTHORITY_REQUIRED | 10,688 | 10,700 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Initial treatment - 6 weekly treatment regimen</p><br/><p>The treatment must be adjuvant to complete surgical resection; AND</p> <p>Patient must have a WHO performance stat... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Resected Stage IIIB, Stage IIIC or Stage IIID malignant melanoma</p><br/><p>Initial treatment - 6 weekly treatment regimen</p><br/><p>The treatment must be adjuvant to complete surgical resection; AND</p> <p>Patient must have a WHO performance stat... | N | N | N | IMMEDIATE | ALL | N | 2020-09-01 | 3,671 |
10706_10701_R | Continuing treatment - 6 weekly treatment regimen | STREAMLINED | 10,701 | 10,706 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment - 6 weekly treatment regimen</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must have previously been iss... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Unresectable Stage III or Stage IV malignant melanoma</p><br/><p>Continuing treatment - 6 weekly treatment regimen</p><br/><p>The treatment must be the sole PBS-subsidised therapy for this condition; AND</p> <p>Patient must have previously been iss... | N | N | N | IMMEDIATE | ALL | N | 2020-09-01 | 3,671 |
10720_10844_R | Maintenance therapy | STREAMLINED | 10,844 | 10,720 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Maintenance therapy</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>Patient must have been commenced on treatment in a specialist unit... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Parkinson disease</p><br/><p>Maintenance therapy</p><br/><p>Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND</p> <p>Patient must have been commenced on treatment in a specialist unit... | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10734_7046_R | Continuing treatment | AUTHORITY_REQUIRED | 7,046 | 10,734 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic spontaneous urticaria</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a clinical immunologist; or</p> <p>Must be treated by an allergist; or</p> <p>Must be treated by a dermatologist; or</p> <p>Must be treated by a gene... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic spontaneous urticaria</p><br/><p>Continuing treatment</p><br/><p>Must be treated by a clinical immunologist; or</p> <p>Must be treated by an allergist; or</p> <p>Must be treated by a dermatologist; or</p> <p>Must be treated by a gene... | N | N | N | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10736_10806_R | Continuing treatment, Whole body | AUTHORITY_REQUIRED | 10,806 | 10,736 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Whole body</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient must have... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10737_10889_R | Continuing treatment, Face, hand, foot | AUTHORITY_REQUIRED | 10,889 | 10,737 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Severe chronic plaque psoriasis</p><br/><p>Continuing treatment, Face, hand, foot</p><br/><p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p> <p>Patient mus... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10738_9614_R | Initial treatment | AUTHORITY_REQUIRED | 9,614 | 10,738 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute lymphoblastic leukaemia</p><br/><p>Initial treatment</p><br/><p>The condition must be expressing the Philadelphia chromosome; or</p> <p>The condition must have the transcript BCR-ABL; AND</p> <p>Patient must have failed prior treatment with P... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute lymphoblastic leukaemia</p><br/><p>Initial treatment</p><br/><p>The condition must be expressing the Philadelphia chromosome; or</p> <p>The condition must have the transcript BCR-ABL; AND</p> <p>Patient must have failed prior treatment with P... | N | N | Y | FULL | ALL | N | 2020-10-01 | 3,671 |
10739_9465_R | Continuing treatment | AUTHORITY_REQUIRED | 9,465 | 10,739 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute lymphoblastic leukaemia</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must not have progressive disease while receiving PBS-subs... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Acute lymphoblastic leukaemia</p><br/><p>Continuing treatment</p><br/><p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p> <p>Patient must not have progressive disease while receiving PBS-subs... | N | N | Y | IMMEDIATE | ALL | N | 2020-10-01 | 3,671 |
10749_10755_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months | STREAMLINED | 10,755 | 10,749 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Patient must ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for less than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Patient must ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10750_10748_R | Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months | STREAMLINED | 10,748 | 10,750 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Patient must ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe pain</p><br/><p>Initial PBS treatment after 1 June 2020 where patient has been treated with opioids for more than 12 months</p><br/><p>The condition must require daily, continuous, long term opioid treatment; AND</p> <p>Patient must ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
10752_10752_R | Continuing PBS treatment after 1 June 2020 | STREAMLINED | 10,752 | 10,752 | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">Palliative ... | <h1>Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1</h1><p>Chronic severe pain</p><br/><p>Continuing PBS treatment after 1 June 2020</p><br/><p>Patient must have previously received PBS-subsidised treatment with this form of this drug for this condition after 1 June 2020.</p> <p align="justify">Palliative ... | N | N | N | IMMEDIATE | ALL | Y | 2020-10-01 | 3,671 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 12